c-erbB-2 is not a major factor in the development of colorectal cancer

J. A. McKay, Joseph Loane, M. M. Ameyaw, H. L. McLeod, V. G. Ross, Graeme Ian Murray, J. Cassidy

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.

Original languageEnglish
Pages (from-to)568-573
Number of pages5
JournalBritish Journal of Cancer
Volume86
Issue number4
DOIs
Publication statusPublished - 2002

Keywords

  • colorectal cancer
  • c-erbB-2
  • immunohistochemistry
  • PCR-RFLP
  • polymorphism
  • prognosis
  • HER2 GENETIC-POLYMORPHISM
  • BREAST-CANCER
  • PROGNOSTIC-SIGNIFICANCE
  • EXPRESSION
  • HER-2/NEU
  • SURVIVAL
  • PROTEIN
  • ADENOCARCINOMA
  • AMPLIFICATION
  • ONCOPROTEIN

Cite this

McKay, J. A., Loane, J., Ameyaw, M. M., McLeod, H. L., Ross, V. G., Murray, G. I., & Cassidy, J. (2002). c-erbB-2 is not a major factor in the development of colorectal cancer. British Journal of Cancer, 86(4), 568-573. https://doi.org/10.1038/sj.bjc.6600127

c-erbB-2 is not a major factor in the development of colorectal cancer. / McKay, J. A.; Loane, Joseph; Ameyaw, M. M.; McLeod, H. L.; Ross, V. G.; Murray, Graeme Ian; Cassidy, J.

In: British Journal of Cancer, Vol. 86, No. 4, 2002, p. 568-573.

Research output: Contribution to journalArticle

McKay, JA, Loane, J, Ameyaw, MM, McLeod, HL, Ross, VG, Murray, GI & Cassidy, J 2002, 'c-erbB-2 is not a major factor in the development of colorectal cancer', British Journal of Cancer, vol. 86, no. 4, pp. 568-573. https://doi.org/10.1038/sj.bjc.6600127
McKay, J. A. ; Loane, Joseph ; Ameyaw, M. M. ; McLeod, H. L. ; Ross, V. G. ; Murray, Graeme Ian ; Cassidy, J. / c-erbB-2 is not a major factor in the development of colorectal cancer. In: British Journal of Cancer. 2002 ; Vol. 86, No. 4. pp. 568-573.
@article{6936c1a780a2401cbaf20389be847f2f,
title = "c-erbB-2 is not a major factor in the development of colorectal cancer",
abstract = "We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8{\%} of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4{\%} of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.",
keywords = "colorectal cancer, c-erbB-2, immunohistochemistry, PCR-RFLP, polymorphism, prognosis, HER2 GENETIC-POLYMORPHISM, BREAST-CANCER, PROGNOSTIC-SIGNIFICANCE, EXPRESSION, HER-2/NEU, SURVIVAL, PROTEIN, ADENOCARCINOMA, AMPLIFICATION, ONCOPROTEIN",
author = "McKay, {J. A.} and Joseph Loane and Ameyaw, {M. M.} and McLeod, {H. L.} and Ross, {V. G.} and Murray, {Graeme Ian} and J. Cassidy",
year = "2002",
doi = "10.1038/sj.bjc.6600127",
language = "English",
volume = "86",
pages = "568--573",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - c-erbB-2 is not a major factor in the development of colorectal cancer

AU - McKay, J. A.

AU - Loane, Joseph

AU - Ameyaw, M. M.

AU - McLeod, H. L.

AU - Ross, V. G.

AU - Murray, Graeme Ian

AU - Cassidy, J.

PY - 2002

Y1 - 2002

N2 - We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.

AB - We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val(655)lle single nucleotide polymorphism, which is associated with an increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects. Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were significantly more likely to express c-erbB-2 than rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour, indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases, PCR-RFLP analysis of the Val(655)lle single nucleotide polymorphism demonstrated that allele Frequencies were identical between colorectal cancer patients and a control group of Caucasian subjects (lle=0.80 and Val=0.20 in each case), indicating that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P > 0.05 in each case), suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer. (C) 2002 Cancer Research UK.

KW - colorectal cancer

KW - c-erbB-2

KW - immunohistochemistry

KW - PCR-RFLP

KW - polymorphism

KW - prognosis

KW - HER2 GENETIC-POLYMORPHISM

KW - BREAST-CANCER

KW - PROGNOSTIC-SIGNIFICANCE

KW - EXPRESSION

KW - HER-2/NEU

KW - SURVIVAL

KW - PROTEIN

KW - ADENOCARCINOMA

KW - AMPLIFICATION

KW - ONCOPROTEIN

U2 - 10.1038/sj.bjc.6600127

DO - 10.1038/sj.bjc.6600127

M3 - Article

VL - 86

SP - 568

EP - 573

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -